The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer

Abstract

Drug metabolism-associated genes have been clarified to play a vital role in the process of cancer cell growth and migration. Nevertheless, the correlation between drug metabolism-associated genes and gastric cancer (GC) has not been fully explored and clarified. This paper has focused on the role of aldehyde dehydrogenase 6 family member A1 (ALDH6A1), a drug metabolism-associated gene, in the immune regulation and prognosis of GC patients. Using several bioinformatics platforms and immunohistochemistry (IHC) assay, we found that ALDH6A1 expression was significantly down-regulated in GC tissues. Moreover, higher expression of ALDH6A1 was related to the better prognosis of GC patients. ALDH6A1 was also found to be involved in the regulation of several immune-associated signatures, including immunoinhibitors. In conclusion, the above results have concluded that aberrant expression of ALDH6A1 might be served as the promising predictor for prognosis and clinical immunotherapy response in GC patients.

Chromosome‐level Asian elephant genome assembly and comparative genomics of long‐lived mammals reveal the common substitutions for cancer resistance

“…As we expected, the A549 cells that with overexpressed long‐lived mammals ALDH6A1 showed inhibited migration compared to A549 cells transfected with the PEGFP control and mouse ALDH6A1 (Figure 4d,e , Figure S10b ). This not only evidenced that ALDH6A1 overexpression could inhibit growth and migration of cancer cells (Cai et al, 2022 ), but also indicated the ALDH6A1 of long‐lived mammals show stronger inhibition of cellular migration of cancer cells. However, there are some subtle differences in migration ability among cells expressed four long‐lived mammals ALDH6A1 .…”

PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy

“…Gastric cancer originates from the epithelial cells of the gastric mucosa, and it poses a significant health challenge due to its aggressive nature, propensity for invading adjacent organs, such as the esophagus, pancreas, and liver, and high incidence of lymph node and distant metastasis [ 16 , 17 ]. Moreover, gastric cancer is the second-most common malignant tumor in China, and it constitutes approximately half of the global number of gastric cancer cases, with an upward trend [ 18 ].…”

Identification of cancer-associated fibroblast-related Ectodysplasin-A as a novel indicator for prognosis and immune response in gastric cancer

“…GO/GSEA enrichment and single-cell data analysis illustrate an association between EDA and immune related pathway, especially interferon-gamma response. Besides perioperative chemotherapy, immunotherapy has been illustrated to have an important effect from third-line treatment to first-line treatment in GC patients [ 30 ]. We revealed that expression of EDA was negatively related to indicated immune checkpoints, suggesting that EDA may be a new biomarker or target for immunotherapy focusing on its effect on cancer-associated fibroblasts.…”